1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Nocturia - Pipeline Review, H1 2016

Nocturia - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 38 pages

Nocturia - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Nocturia - Pipeline Review, H1 2016’, provides an overview of the Nocturia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Nocturia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nocturia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Nocturia
- The report reviews pipeline therapeutics for Nocturia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Nocturia therapeutics and enlists all their major and minor projects
- The report assesses Nocturia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Nocturia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Nocturia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Nocturia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Nocturia - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Nocturia Overview 6
Therapeutics Development 7
Pipeline Products for Nocturia - Overview 7
Nocturia - Therapeutics under Development by Companies 8
Nocturia - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Nocturia - Products under Development by Companies 12
Nocturia - Companies Involved in Therapeutics Development 13
Allergan Plc 13
Astellas Pharma Inc. 14
Sumitomo Dainippon Pharma Co., Ltd. 15
Vantia Therapeutics 16
Nocturia - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
afacifenacin - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
ASP-7035 - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
ASP-7398 - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
desmopressin acetate - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
fedovapagon - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
Paxerol - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
Nocturia - Recent Pipeline Updates 32
Nocturia - Dormant Projects 34
Nocturia - Product Development Milestones 35
Featured News and Press Releases 35
Feb 02, 2010: Vantia Therapeutics Initiates Phase IIb Clinical Trial Of VA106483 For Nocturia 35
Jun 29, 2009: Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-Diuretic Effect In Phase IIa Trial In Nocturia 35
Mar 24, 2009: Vantia Therapeutics' VA106483 Completes Phase IIa Trial 36
Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 37
Disclaimer 38

List of Tables
Number of Products under Development for Nocturia, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Late Stage Development, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 10
Comparative Analysis by Early Stage Development, H1 2016 11
Products under Development by Companies, H1 2016 12
Nocturia - Pipeline by Allergan Plc, H1 2016 13
Nocturia - Pipeline by Astellas Pharma Inc., H1 2016 14
Nocturia - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 15
Nocturia - Pipeline by Vantia Therapeutics, H1 2016 16
Assessment by Monotherapy Products, H1 2016 17
Number of Products by Stage and Target, H1 2016 19
Number of Products by Stage and Mechanism of Action, H1 2016 21
Number of Products by Stage and Route of Administration, H1 2016 23
Number of Products by Stage and Molecule Type, H1 2016 25
Nocturia Therapeutics - Recent Pipeline Updates, H1 2016 32
Nocturia - Dormant Projects, H1 2016 34

List of Figures
Number of Products under Development for Nocturia, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Clinical Stage Development, H1 2016 10
Assessment by Monotherapy Products, H1 2016 17
Number of Products by Targets, H1 2016 18
Number of Products by Stage and Targets, H1 2016 18
Number of Products by Mechanism of Actions, H1 2016 20
Number of Products by Stage and Mechanism of Actions, H1 2016 20
Number of Products by Routes of Administration, H1 2016 22
Number of Products by Stage and Routes of Administration, H1 2016 22
Number of Products by Molecule Types, H1 2016 24
Number of Products by Stage and Molecule Types, H1 2016 24

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.